We are live on ! Find out more

2,378 hedge funds and large institutions have $176B invested in Pfizer in 2019 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 926 increasing their positions, 1,102 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $1.74B | Put options by funds: $1.35B

23% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 75

2% more capital invested

Capital invested by funds: $173B → $176B (+$2.73B)

1% less funds holding

Funds holding: 2,3922,378 (-14)

0.68% less ownership

Funds ownership: 77.53%76.85% (-0.68%)

1% less funds holding in top 10

Funds holding in top 10: 202199 (-3)

16% less repeat investments, than reductions

Existing positions increased: 926 | Existing positions reduced: 1,102

Holders
2,378
Holders Change
-14
Holders Change %
-0.59%
% of All Funds
51.64%
Holding in Top 10
199
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-1.49%
% of All Funds
4.32%
New
92
Increased
926
Reduced
1,102
Closed
75
Calls
$1.74B
Puts
$1.35B
Net Calls
+$392M
Net Calls Change
+$151M
Name Holding Trade Value Shares
Change
Change in
Stake
MCM
1001
Mengis Capital Management
Oregon
$3.3M +$1.88M +47,388 +144%
FNBTCON
1002
First National Bank & Trust Co of Newtown
Pennsylvania
$3.3M -$50.2K -1,265 -2%
GSBTD
1003
Glenview State Bank Trust Department
Illinois
$3.29M -$21.3K -536 -0.7%
VNA
1004
Valley National Advisers
Pennsylvania
$3.28M -$34.8K -876 -1%
CC
1005
ClearArc Capital
Ohio
$3.27M -$418K -10,523 -12%
BO
1006
Bank OZK
Arkansas
$3.27M -$52.8K -1,329 -2%
LWCFA
1007
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$3.26M +$744K +18,730 +31%
ACM
1008
Advent Capital Management
New York
$3.25M -$1.05M -26,350 -25%
AAM
1009
Auxier Asset Management
Oregon
$3.25M +$74.3K +1,871 +2%
WFG
1010
Wills Financial Group
Virginia
$3.25M -$5.72K -144 -0.2%
SFA
1011
Sequoia Financial Advisors
Ohio
$3.23M -$117K -2,959 -4%
SA
1012
Strategic Advisors
New York
$3.22M -$10.1K -255 -0.3%
CC
1013
Chicago Capital
Illinois
$3.22M -$7.11K -179 -0.2%
FB
1014
Fulton Bank
Pennsylvania
$3.22M +$107K +2,701 +4%
PCM
1015
Princeton Capital Management
New Jersey
$3.19M -$137K -3,456 -4%
WSC
1016
Wellington Shields & Co
New York
$3.19M -$8.66K -218 -0.3%
GC
1017
Grimes & Company
Massachusetts
$3.17M -$17K -427 -0.5%
JIC
1018
Joel Isaacson & Co
New York
$3.17M -$808K -20,358 -21%
BWAM
1019
Boyd Watterson Asset Management
Ohio
$3.15M -$34.6K -871 -1%
KIG
1020
Kessler Investment Group
Indiana
$3.15M -$222K -5,584 -7%
DCM
1021
Dupont Capital Management
Delaware
$3.15M
WP
1022
WMS Partners
Maryland
$3.15M +$290K +7,300 +11%
LCP
1023
Legacy Capital Partners
Wisconsin
$3.14M +$29.7K +749 +1%
RMSCM
1024
R.M. Sincerbeaux Capital Management
New York
$3.13M -$70.6K -1,779 -2%
TC
1025
TownSquare Capital
Utah
$3.12M -$346K -8,709 -9%

PFE Hedge Fund Activity: Q2 2019 in Review

2,378 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2019, worth a combined $176B — up 1.6% from $173B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new PFE positions and 75 closed out — a net gain of 17 holders — while 926 added to existing stakes and 1,102 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $2.49B. The largest seller was BlackRock, cutting an estimated $829M.

  • 2,378 institutional investors held Pfizer (PFE) as of Q2 2019, down from 2,392 in Q1 2019.
  • Funds reported $176B of Pfizer stock for Q2 2019, up 1.6% quarter-over-quarter.
  • 92 funds opened new Pfizer positions in Q2 2019 and 75 closed out, a net change of +17 holders.
  • The largest Pfizer buyer in Q2 2019 was Wellington Management Group, an estimated $2.49B added.
  • The largest Pfizer seller in Q2 2019 was BlackRock, an estimated $829M sold.

Based on aggregated 13F filings for Q2 2019.